Inspired to improve the lives of millions of patients and their families living with food allergies worldwide, Aravax is dedicated to revolutionising the treatment of food allergy by developing next-generation, disease-modifying immunotherapies that are safer and more convenient than existing approaches.
Our Proprietary Platform
Although food allergies are on the rise, patients remain underserved with a critical need for better treatments.
Aravax’s next-generation immunotherapies use proprietary peptides designed to precisely retrain the immune system to tolerate specific foods with minimal risk of treatment-induced acute allergic reactions.
Phase 2 Clinical Trials
Aravax’s lead product, PVX108 is currently being studied in an international Phase 2 trial for the treatment of peanut allergy.
The trial is being run under an IND in children and adolescents with peanut allergy at clinics in the United States and in Australia. The trial is fully enrolled.
Latest News
- Aravax to Communicate Results of its Phase 2 Clinical Trial of PVX108, a Novel immunotherapy for the Treatment of Peanut Allergy, at Major Scientific Meetings in November 2026 5 October 2026
- Aravax Awarded FDA Fast Track Designation for PVX108, a Next-Generation Immunotherapy for the Treatment of Peanut Allergy 3 August 2026
